ICER Panel Rejects MDMA-Assisted Therapy, Highlights Evidence Gaps and Study Flaws in 14-1 Vote Post published:May 31, 2024 Post category:Analysis/News/Pα+
Patients, Practitioners, Researchers and Public Submit Comments Ahead of FDA Advisory Committee on MDMA Post published:May 29, 2024 Post category:Analysis/Pα+
What to Expect: FDA Advisory Committee Set to Review MDMA-Assisted Therapy for PTSD Post published:May 27, 2024 Post category:Analysis/Pα+
California’s Latest Psychedelics Bill Dies in Committee Post published:May 17, 2024 Post category:Analysis/News
“We’re Going to See Demand for This Go Through the Roof”: VA Under Secretary for Health Shares How the Agency Is Preparing for MDMA, Psilocybin Therapies Post published:May 15, 2024 Post category:Analysis/News
Industry and Researchers Respond to ICER Report on MDMA-Assisted Therapy, Which Maintains Lykos’ Clinical Evidence Is “Insufficient” Post published:May 14, 2024 Post category:Analysis/News
Breaking: AbbVie Inks Deal with Gilgamesh Pharmaceuticals Post published:May 13, 2024 Post category:Analysis/News/Pα+
European Medicines Agency CMO Talks Psychedelics and Their Therapeutic Use in Live Q&A Post published:May 9, 2024 Post category:Analysis/News/Pα+
The Church of the Eagle and the Condor Settles with Federal Agencies, Can Continue Importing and Using Ayahuasca Post published:May 8, 2024 Post category:Analysis/News
FDA Advisory Committee to Review Lykos Therapeutics’ MDMA-Assisted Therapy in Early June Post published:May 7, 2024 Post category:Analysis/News/Pα+